clinical trial · NCT07643623
Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.·phase3·recruiting·n = 720
Resectable Gastric/Gastroesophageal Junction Adenocarcinomategafur, Gimeracil and Oteracil Potassium CapsulesSintilimab PlaceboSintilimabIpilimumab N01Oxaliplatin for injectionIpilimumab N01 Placebo
brief summary
This is a Randomized, Double-Blind, Phase II/III Clinical Study of the Efficacy and Safety of Sintilimab Combined with Chemotherapy With or Without Ipilimumab N01 in Perioperative Treatment of Resectable Gastric/Gastroesophageal Junction Adenocarcinoma.
started
Jul 31, 2026
primary completion
Dec 31, 2031
completion
Dec 31, 2031
last updated
Aug 14, 2026
official title
A Randomized, Double-Blind, Phase II/III Clinical Study of the Efficacy and Safety of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Perioperative Treatment of Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol